Brain hyperthermia as physiological and pathological phenomena.
Although brain metabolism consumes high amounts of energy and is accompanied by intense heat production, brain temperature is usually considered a stable, tightly "regulated" homeostatic parameter. Current research, however, revealed relatively large and rapid brain temperature fluctuations (3-4 degrees C) in animals during various normal, physiological, and behavioral activities at stable ambient temperatures. This review discusses these data and demonstrates that physiological brain hyperthermia has an intra-brain origin, resulting from enhanced neural metabolism and increased intra-brain heat production. Therefore, brain temperature is an important physiological parameter that both reflects alterations in metabolic neural activity and affects various neural functions. This work also shows that brain hyperthermia may be induced by various drugs of abuse that cause metabolic brain activation and impair heat dissipation. While individual drugs (i.e., heroin, cocaine, methamphetamine, MDMA) have specific, dose-dependent effects on brain and body temperatures, these effects are strongly modulated by an individual's activity state and environmental conditions, and change dramatically during the development of drug self-administration. Thus, brain thermorecording may provide new information on the central effects of various addictive drugs, drug-activity-environment interactions in mediating drugs' adverse effects, and alterations in metabolic neural activity associated with the development of drug-seeking and drug-taking behavior. While ambient temperatures and impairment of heat dissipation may also affect brain temperature, these environmental conditions strongly potentiate thermal effects of psychomotor stimulant drugs, resulting in pathological brain overheating. Since hyperthermia exacerbates drug-induced toxicity and is destructive to neural cells and brain functions, use of these drugs under activated conditions that restrict heat loss may pose a significant health risk, resulting in both acute life-threatening complications and chronic destructive CNS changes.
Kiyatkin
Eugene A
EA
Cellular Neurobiology Branch, National Institute on Drug Abuse-Intramural Research Program, National Institutes of Health, DHHS, 5500 Nathan Shock, Baltimore, MD 21224, USA. ekiyatki@intra.nida.nih.gov
D018759:Adrenergic Uptake Inhibitors / Q000009:adverse effects; D000818:Animals; D001831:Body Temperature / Q000502:physiology; D001927:Brain Diseases / Q000139:chemically induced / Q000503:physiopathology*; D005334:Fever / Q000473:pathology* / Q000503:physiopathology*; D006801:Humans; D009294:Narcotics / Q000009:adverse effects
D018759:Adrenergic Uptake Inhibitors; D009294:Narcotics